Levulan® Kerastick®

(aminolevulinic acid HCl) for Topical Solution, 20%

Welcome to DUSA » For Healthcare Professionals » Levulan® Kerastick®

Levulan® Kerastick® with BLU-U® Blue Light:  A Unique Therapeutic Approach to Manage Actinic Keratoses

What is Levulan PDT?

Levulan PDT is Directly Observed Therapy that provides high clearance with low downtime for appropriate actinic keratosis patients.1*

Who are appropriate AK patients?       

  • Patients with few minimally to moderately thick AKs of the face or scalp                                          
  • Patients with multiple minimally to moderately thick AKs of the face or scalp  
  • Patients with minimally to moderately thick AKs in sensitive areas on the face or scalp  

Why is patient adherence important?

Appropriate patient selection requires the evaluation of a range of factors, such as AK lesion characteristics, patient expectations, patient history and patient adherence. Patient adherence is closely linked to treatment outcome which makes patient selection very important in order to reduce risk of nonadherence.2,3

Among the patients at risk for nonadherence are those who:

  • Are elderly
  • Have asymptomatic disease
  • Have poor understanding of the condition
  • Lack belief in benefit of the treatment

Among the factors associated with nonadherence are:

  • Side effects or fear of side effects
  • Complexity of the drug regimen
  • Cost of treatment/poor health coverage

 Poor medication adherence is reaching crisis proportions in the US2

A 2009 survey by the Senior Citizens League found4

  • 42% of the elderly had either postponed filling their prescription or were reducing their dosage

Another survey found5

  • 3 of every 4 American consumers report not always taking their prescription medicine as directed
  • 49% said they had forgotten to take a prescribed medicine
  • 31% had not filled a prescription they were given
  • 24% had taken less than the recommended dose

Why choose Levulan PDT?

Levulan PDT is an effective therapy that will not only add value for your practice, but it may also be the right treatment choice for your new AK patients or those who are unwilling to repeat a prior topical treatment. In addition, our directly observed therapy can impact patient adherence.   

  • Levulan PDT is initiated and completed in an in-office setting
  • Physician-controlled treatment is administered by a qualified healthcare professional
  • No prescription for the patient to fill
  • No daily medication for the patient to remember
  • The 2-part, 2-office visit treatment is completed in less than 24 hours
  • Recovery begins when treatment ends

 

Make Levulan PDT your FIRST treatment choice for your appropriate AK patients.

* Patients treated with Levulan PDT should avoid exposure of the photosensitized lesions to sunlight or prolonged or intense light for at least 40 hours.

1 Levulan Kerastick Prescribing Information, DUSA Pharmaceuticals, Inc.

2 Enhancing Prescription Medicine Adherence: A National Action Plan. National Council on Patient Information and Education. August 2007.

3 Gupta G, et al. Adherence to topical dermatological therapy: lessons from oral drug treatment. BR J Dermatol. 209; 161:221-227.

4 http://seniorjournal.com//NEWS/Money/2009/20090722-SenCitSkippingMedicine.htm

5 Take as Directed: A Prescription Not Followed. Research conducted by The Polling Company™. National Community Pharmacists Association. December 15, 2006.

 

Important Risk Information
Levulan® Kerastick® plus blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.

Application of Levulan® Kerastick® should involve either scalp or face lesions, but not both simultaneously. Levulan® Kerastick® should not be applied to the periorbital area or allowed to contact ocular or mucosal surfaces. Excessive irritation may be experienced if this product is applied under occlusion.

Contraindicated in patients with cutaneous photosensitivity at wavelengths of 400-450 nm, porphyria, or known allergies to porphyrins, and in patients with known sensitivity to any of the components of the Levulan Kerastick for Topical Solution.

Levulan® Kerastick® has not been tested on patients with inherited or acquired coagulation defects. It is possible that concomitant use of other known photosensitizing agents might increase the photosensitivity reaction of actinic keratoses treated with the Levulan® Kerastick®.

Patients should avoid exposure of the photosensitive treatment sites to sunlight or bright indoor light for at least 40 hours after Levulan® Kerastick® application. Exposure may result in a stinging and/or burning sensation and may cause erythema or edema of the lesions. Patients should protect treated lesions from the sun by wearing a wide-brimmed hat or similar head covering of light-opaque material. Sunscreens will not protect against photosensitivity reactions caused by visible light.

Transient local symptoms of stinging and/or burning, itching, erythema, and edema were observed in all clinical studies. Severe stinging and/or burning at one or more lesions being treated was reported by at least 50% of patients at some time during treatment. However, less than 3% of patients discontinued light treatment due to stinging and/or burning.

During light treatment, both patients and medical personnel should be provided with blue blocking protective eyewear, as specified in the BLU-U operating instructions to minimize ocular exposure.

WEB 1460 Rev D